Covaxin Has 93.4 Per Cent Efficacy Against Severe COVID-19 Cases, Overall Efficacy At 77.8 Per Cent: Bharat BiotechBharat Biotech (Pic Via Wikipedia)

Hyderabad-based vaccine maker Bharat Biotech on Friday (2 July) announced that the third stage trials have shown that Covaxin provides greater protection against emerging B.1.617.2 (Delta) variant of COVID-19, with an efficacy rate of 65.2 per cent, reports Times of India.

Bharat Biotech also shared that in the case of mild, moderate and severe COVID-19 disease, Covaxin demonstrated the efficacy of 77.8 per cent and that in the case of prevention of severe disease alone, the efficacy of the vaccine stood at 93.4 per cent.

The development comes as Bharat Biotech released the data of the third phase trial of the Covaxin, that included around 25,800 participants.

"130 cases of symptomatic COVID-19 were reported in 16,973 (0.77 per cent) participants with follow-up at least two weeks after the second vaccination; 24 occurred in the vaccine group and 106 in placebo recipients giving an overall vaccine efficacy of 77.8 per cent," a study published in the pre-print server medRxiv said.

"Sixteen cases, one vaccinee and 15 placebo recipients, met the severe symptomatic COVID-19 case definition giving a vaccine efficacy of 93.4 per cent," the study said.

The efficacy of the vaccine against asymptomatic COVID-19 was 63.6 per cent, the study said.

It further added that the Covaxin conferred 65.2 per cent protection against the B.1.617.2 or the Delta variant of concern of Covid-causing SARS CoV-2 virus.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber